A contemporary analysis of induction immunosuppression in pediatric lung transplant recipients

• Published in: Transplant international Vol. 27; no. 2; pp. 211 - 218
• Main Authors: Hayes, Don, Kirkby, Stephen, Wehr, Allison M., Lehman, Amy M., McConnell, Patrick I., Galantowicz, Mark, Higgins, Robert S., Whitson, Bryan A.
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01.02.2014
• Subjects: Adolescent; Alemtuzumab; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized - therapeutic use; Antilymphocyte Serum - therapeutic use; Cadaver; Child; children; Female; Graft Rejection; Graft Survival; Humans; immunosuppression; Immunosuppression - methods; Immunosuppressive Agents - therapeutic use; induction; lung transplantation; Lung Transplantation - methods; Lung Transplantation - mortality; Male; pediatric lung transplantation; Proportional Hazards Models; Recombinant Fusion Proteins - therapeutic use; Retrospective Studies; survival; Survival Analysis; Treatment Outcome; immunosuppression; lung transplantation; pediatric lung transplantation; induction; children; survival
• ISSN: 0934-0874; 1432-2277
• DOI: 10.1111/tri.12240

Summary There is an increasing trend in the use of induction immunosuppression in children undergoing lung transplantation (LTx). To evaluate the effect of this practice on survival, the United Network for Organ Sharing (UNOS) was queried from 1987 to 2012, restricting analysis to transplant patients 6–17 years old from 2001 to 2012, who received no induction (NONE) or induction (INDUCED) with the contemporary agents of basiliximab, alemtuzumab, thymoglobulin, antilymphocyte globulin (ALG), or antithymocyte globulin (ATG). Of 23 951 lung transplants, 330 met inclusion criteria with 177 (54%) being INDUCED. Of the INDUCED agents, 121 (68%) were basiliximab, 3 (2%) alemtuzumab, and 53 (30%) ALG/ATG/thymoglobulin. The mean patient age was 13.6 (SD = 3.2) and 14 (SD = 3.0) years for the INDUCED and NONE groups, respectively. The median survival in the INDUCED group was 77.4 months (95% CI: 46.1, 125.6) compared with 50.8 months (95% CI: 42.9, 61.3) for the NONE (log‐rank P‐value = 0.3601). The most common cause of death was due to allograft failure or pulmonary complications with only one patient dying from post‐transplant lymphoproliferative disorder. The estimated hazard ratio for INDUCED versus NONE was 0.859 (95% CI: 0.620, 1.191; P = 0.3618); there were no significant confounders or effect modifiers among the demographic and clinical variables. In conclusion, antibody‐based induction immunosuppression with contemporary agents had a trend toward a protective, but not statistically significant, effect in 6‐ to 17‐year‐old patients.